GE HealthCare announced that it will serve as the leading industrial partner in the COMPASS consortium, a five‑year, €50.5 million Horizon Europe initiative aimed at improving precision cardio‑oncology care across Europe.
The consortium, funded under the Innovative Health Initiative, brings together more than sixty partners, including King's College London, leading academic institutions, hospitals, and technology companies, to develop early‑detection tools for cardiovascular risks in cancer patients.
GEHC will integrate its imaging platforms and AI‑enabled software into the consortium’s research and clinical workflows, building on recent acquisitions and product launches such as Intelerad, Photonova Spectra, and Flyrcado, positioning the company to accelerate next‑generation diagnostics.
Cardio‑oncology is a rapidly expanding market, driven by the fact that cardiovascular complications are the second leading cause of death in cancer patients and survivors, accounting for up to 10% of mortality. By joining COMPASS, GEHC expands its presence in this high‑growth segment and leverages EU funding to foster collaboration that could speed product development and market adoption.
Eigil Samset, General Manager of Cardiology Solutions, said: “This initiative is well positioned to enable patient‑centered cancer care that takes cardiotoxicity risk into account, supports the early detection of cardiotoxic side‑effects, and promotes long‑term heart health for oncology patients. We are honored to play an integral part as industry lead in this multidisciplinary collaboration which brings together the expertise of leading European academic, clinical, industry…”,
GEHC’s recent financial performance underscores its capacity to invest in such initiatives. Q4 2025 revenues reached $5.7 billion, up 7.1% YoY, with a net income margin of 10.3%; full‑year 2025 revenues were $20.6 billion, up 4.8% YoY, and a net income margin of 10.1%. The company is guiding for 3‑4% organic revenue growth in 2026 and an adjusted EBIT margin of 15.8‑16.1%, reflecting confidence in its growth strategy and the added value of the COMPASS partnership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.